OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	114
Editorial Board	112
Editorial Board	78
Editorial Board	74
Genetics of pubertal timing	64
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	57
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	55
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	53
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	51
Menopausal hormone therapy for the management of osteoporosis	48
Regulation of bone mass: A splendid Orchestra	45
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	44
Coronavirus disease 2019 and vitamin D	44
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	41
Editorial Board	41
Sexual health and contraception in the menopause journey	40
The role of androgens in transgender medicine	40
Editorial Board	39
Immune checkpoint inhibitor-related thyroid dysfunction	39
Prenatal exposure to phthalate esters and its impact on child development	39
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	38
Remnant lipoprotein particles and cardiovascular disease risk	34
Cardiometabolic outcomes of early onset hypogonadism in males	34
Haematological actions of androgens	32
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	31

Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	31
Editorial Board	28
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	27
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	27
Medullary thyroid cancer - An update	26
Type 1 diabetes related to immune checkpoint inhibitors	26
Endocrine-disrupting chemicals and behaviour: A high risk to take?	26
The effect of osteoporosis treatment on bone mass	26
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	26
Metabolic complications and their mechanisms in patients with craniopharyngioma	25
Radioiodine therapy in the different stages of differentiated thyroid cancer	25
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	24
Non-oestrogen-based and complementary therapies for menopause	24
Immune checkpoint inhibitor-related hypophysitis	23
Pathophysiology of thyroid-associated orbitopathy	23
Approach to patients with elevated low-density lipoprotein cholesterol levels	23
Safety of androgen therapy in men with prostate cancer	23
Hormone therapy for menopause and premature ovarian insufficiency	23
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	22
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	22
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	22
Editorial Board	22
History of androgens and androgen action	21
The role of hormone therapy in urogenital health after menopause	21
Localization in primary hyperparathyroidism	21
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	21
Editorial Board	20
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	20
Genotype-phenotype correlations in Graves’ disease	20
Editorial Board	20
Genetics of anti-Müllerian hormone and its signaling pathway	19
Endocrine disrupting chemicals and bone	19
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	18
Hyponatremia and bone pathophysiology: an integrated preclinical and clinical perspective	18
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	18
Care quality improvement in differences of sex development	17
Hormone replacement in disorders of sex development, and long-term effects	17
Preface	17
Exercise and physical activity in individuals at risk of fracture	16
COVID-induced thyroid autoimmunity	16
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	16
Chemokines in thyroid autoimmunity	15
Editorial Board	15
Anaplastic thyroid cancer: An update	15
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	15
Preface	15
The epidemiology of disorders of sex development	15
Covid-19 and endocrinology	14

Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	14
Paraneoplastic autoimmune hypophysitis: An emerging concept	14
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	14
Strategies for improving the knowledge of patients and carers	14
Editorial Board	14
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	13
Endocrine abnormality in paraneoplastic syndrome	13
Menopausal hormone therapy in women with medical conditions	12
Quality of life in thyroid cancer	12
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	11
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	11
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	11
How best to monitor the specific side effects of medical treatments of Cushing’s disease	11
Surgical treatment of thyroid cancer: Established and novel approaches	11
SARS-CoV-2 infection and its effects on the endocrine system	11
Long-term thionamide antithyroid treatment of Graves' disease	10
Real-world value of cabergoline in the treatment of acromegaly	10
Genetics of 46,XY gonadal dysgenesis	10
Management of patients with statin intolerance	10
Adolescent primary hyperparathyroidism	10
Androgen-based therapies in women	10
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	10
Editorial Board	9
COVID-19 vaccination and thyroiditis	9
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	9
Regulation of bone mass in endocrine diseases including diabetes	9
Current medical treatment and perspective in gonadotroph tumors	9
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	9
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	9
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	9
Burosumab: Current status and future prospects	9
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	8
Pituitary and SARS CoV-2: An unremitting conundrum	8
Androgens part 2: Emerging areas	8
Associations of prenatal exposure to phthalates and one phthalate substitute with anthropometric measures in early life: Results from the German LIFE Child cohort study	8
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	8
Inherited fibroblast growth factor 23 excess	8
Phthalates, ovarian function and fertility in adulthood	7
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	7
Vitamin D deficiency or resistance and hypophosphatemia	7
Novel androgen therapies including selective androgen receptor modulators	7
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	7
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	6
Androgen therapy for women after menopause	6
Morbidity and mortality in men: Role of androgens	6
Innovative therapeutics in acromegaly	6
Heritable hyperparathyroidism: Genetic insights and clinical implications	6
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	6
New advances in menopause symptom management	6
Traumatic brain injury and hypopituitarism	6
Tumor-induced osteomalacia: An overview	6
Broader impact and outcome of human NR5A1/SF1 variants	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
In utero exposure to phthalates and reproductive toxicity in rodents	5
Genetics of ovarian insufficiency and defects of folliculogenesis	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Pituitary dysfunction due to sports injuries	5
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	5
Primary hyperparathyroidism	4
The pathophysiology of hypophosphatemia	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4
Genetics of cryptorchidism and testicular regression	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
Thyroid hormone system disrupting chemicals	4
Editorial Board	4
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	4
Androgens, sports, and detection strategies for anabolic drug use	4
Editorial Board	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Premature ovarian insufficiency, early menopause, and induced menopause	4